Year: 2025
Type: article
Abstract: BACKGROUND: Pancreatic cancer is estimated to become the second leading cause of cancer-related death by 2030 because of high malignancy, late diagnosis, inefficient therapy, and a lack of available screening for early detection. OBJECTIVES: This article presents current clinical data supporting the use of serum biomarker signatures as a modality for early pancreatic ductal adenocarcinoma (PDAC) diagnosis and treatment. METHODS: A clinical case study highlights the use of serum biomarker signatures in PDAC diagnosis. Clinical guidelines on PDAC were obtained from the National Comprehensive Cancer Network, the National Cancer Institute, StatPearls Publishing, the American Cancer Society, and the Pancreatic Cancer Detection Consortium. FINDINGS: Screening barriers involve a low incidence and histologic heterogeneity of disease, as well as a need for prospective multicenter analysis of proposed biomarkers. Because the poor prognosis of PDAC is attributed to late detection, the development of a clinical guideline for biomarker-based screening warrants interprofessional awareness and advocacy in oncology clinical practice.
Author: Christina Zhang
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4408508918